INBS Stock Analysis: Buy, Sell, or Hold?
INBS - Intelligent Bio Solutions Inc. Common Stock
$2.24
0.01 (0.45%)
▲
5d:
+4.19%
30d:
-11.81%
90d:
-28.21%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 21, 2026
Get Alerted When INBS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: INBS shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: INBS shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: INBS is currently trading at $2.24, which is considered oversold relative to its 30-day fair value range of $2.25 to $2.47. From a valuation perspective, the stock is trading at a discount (Forward PE: -0.4) compared to its historical average (13.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, INBS is in a downtrend. The price is currently testing key support at $2.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.00 (+435.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INBS is in a downtrend. The price is currently testing key support at $2.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.00 (+435.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.25 -
$2.47
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 435.7% below Wall St target ($12.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$2.25 -
$2.47
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.24
Resistance Level
$2.68
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.43
Wall Street Target
$12.00
(+435.7%)
Revenue Growth (YoY)
45.5%
Profit Margin
-296.8%
PE vs Historical
-0.4 vs 13.0
CHEAP
Share & Embed Analysis
Last updated: July 05, 2026 10:12 AM ET
Data refreshes hourly during market hours. Next update: 11:12 AM
Data refreshes hourly during market hours. Next update: 11:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INBS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$75 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 58 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$240 | 65 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 65 BUY |